Poland has found itself in a situation that only a few years ago would have seemed politically unthinkable: following a non-final ruling by a court in Brussels, it may be forced to pay approximately PLN 5.64 billion, or roughly PLN 6 billion, for COVID-19 vaccines that it did not collect and no longer needs. The case concerns a contract signed by the European Commission with Pfizer and BioNTech in 2021, at the height of pandemic uncertainty, when EU member states were seeking to secure vaccine supplies for the years ahead.
At the heart of the problem is the fact that the logic of decisions made during the crisis later collided with post-crisis reality. When the agreement was signed, European governments were still worried about vaccine shortages and further waves of infection. But already in 2022, as pandemic pressure declined and the geopolitical situation changed following Russia’s invasion of Ukraine, Poland refused to continue implementing the contract. Warsaw argued that the circumstances had changed fundamentally and that continuing to receive enormous batches of the vaccine made no medical or economic sense. The Brussels court, however, did not accept those arguments.
The ruling is especially painful for Poland not only because of the amount involved, but also because of its practical consequences. According to information provided by the Ministry of Health and the Polish Press Agency, the case concerns around 64 million doses that Poland would be required to take delivery of. Health Minister Jolanta Sobierańska-Grenda said openly that these would most likely have to be destroyed, because they would no longer be used by patients. According to the ministry, this means billions of złoty spent not on treatment, diagnostics, or emergency care, but on a product that may be discarded after delivery.
It is precisely this aspect that gives the case its political and symbolic dimension. PLN 6 billion is not an abstract figure in a spreadsheet, but an amount that the government is now comparing with annual spending on key areas of public healthcare. The Ministry of Health points out that this is equivalent to the yearly cost of oncology drugs, emergency medical services, or part of specialist care for children and young people. In this light, the dispute with Pfizer becomes not only a contractual lawsuit, but also a story about the price of strategic mistakes made under conditions of pressure and chaos.
The current government is trying to shift the political responsibility onto the previous administration, arguing that it was that government which committed Poland to a massive order despite earlier purchases and already existing stockpiles. According to figures presented by the Ministry of Health, at the time this additional commitment was made, Poland had already contracted nearly 109 million doses, while 30 million unused vaccines were sitting in storage. The additional order volume for the years 2022–2024 was said to amount to nearly 89 million doses. The ministry also recalls that the Supreme Audit Office questioned the rationality of these decisions.
At the same time, the case also illustrates the hard logic of contracts concluded at the EU level. Reuters reported that the court rejected the arguments put forward by Poland and Romania concerning changed pandemic conditions, the war in Ukraine, and an alleged abuse of dominant position by Pfizer. In the court’s view, contracts that formed the basis of the European Union’s joint response to the pandemic remain binding even when the political atmosphere changes and demand for vaccinations falls sharply. After the ruling, Pfizer itself emphasized the importance of contractual commitments for the solidarity-based response of EU member states to the health crisis.
It is worth remaining precise, however: it is not the case that the matter has already been definitively and finally settled. The Ministry of Health stresses that this is a non-final judgment and that Poland intends to use all available legal avenues to change it or limit its consequences. This is an important reservation, because political headlines suggesting that “Poland already has to pay PLN 6 billion” oversimplify the situation. A more accurate formulation would be that Poland has lost a very important first stage of the dispute and now faces a real risk of having to pay approximately PLN 5.64 billion plus interest.
Regardless of how the case proceeds, it already serves as a political and institutional warning. It shows that decisions taken under extraordinary circumstances can burden a state long after the crisis itself has passed. It also shows how difficult it is for governments to withdraw from major international contracts, even when their practical rationale has almost completely disappeared. If Poland ultimately is forced to pay billions for millions of unnecessary doses, this will become one of the most costly symbols of pandemic excess and of a procurement policy carried out without a safe exit strategy.
